Medicare Part D: Closing the Coverage Gap

Signed into law on February 9, 2018, the Bipartisan Budget Act (BBA) of 2018 entails significant adjustments to consumer spending under the Medicare Part D prescription drug program1. Beginning in 2019, the period of out-of-pocket expenses in Medicare, known colloquially as the coverage gap or donut hole, will be fully covered for beneficiaries. By requiring higher payments from pharmaceutical manufacturers,

Read More

Biosimilars in LATAM: So, what’s going on?

  By Sean Skulski Latin America (LATAM) remains a rich, untapped market for the commercialization of biosimilars. Based on a biologic drug (reference product) whose patent has expired, biosimilars are “copycat drugs” that demonstrate proven bioequivalence to the reference product. Unlike generic drugs (chemical products), which are identical to a branded drug, biosimilars are only similar to a reference product;

Read More

China has its eyes on biosimilars

Pricentric Brief: China has its eyes on biosimilars by Sean Skulski   Roche’s Herceptin is experiencing a shortage in China due to swift uptake of the drug following China’s implementation of a new health plan While Herceptin biosimilars are finding traction in the US and Europe, China has yet to receive access to any copycat products China is adamantly paving

Read More

Contact Alliance